Breast cancer, affecting primarily women, is one of the most common cancers with increasing survival rates, yet treatment remains an area for improvement.1 As of 2019, female breast cancer has the highest rates of new diagnoses and is the second highest in number of cancer-related deaths in ...
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer Although early breast cancer (BC) is highly curable, advanced or metastatic disease poses numerous challenges in terms of medical management and treatment ... CS Paola,G Daniele - 《Drug Design Development &...
Last year, results from the phase 3TH3RESA trial, which were presented at the European Cancer Congress, showed that T-DM1 nearly doubled progression-free survival, compared with the physician's choice of treatment. The 602 participants in that trial had advanced metastatic disease and had alread...
So far, TMS therapy has only been approved by the FDA for the treatment of major depression. However, multiple studies have shown that it can be very effective for fibromyalgia as well. Pain associated with fibromyalgia is caused by muscles locally and by the brain’s perception of pain signa...
Myongji Hospital said it has replaced its radiation cancer treatment machine with VitalBeam, the latest linear accelerator.The newly installed machine, VitalBeam, utilizes advanced three-dimensional stereoscopic imaging to accurately target and eliminate
We have this for the icosapent ethyl in reducing both secondary and primary prevention and those triglyceride-rich lipo-protein, but bempedoic acid is the first one we have for LDL-based therapies as a statin add-on.Q: How does bempedoic acid fit into the treatment algorithm as the first ...
Cone launched its Breast Cancer Awareness Collection with a nod to pink, partnering with the Alight Program, which provides financial, educational, and emotional support to women and families navigating diagnosis and treatment. Secondly, Cone released its Pride Selvage Community...
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer.The ...
Last yearanother study led by Janelsins—one of the largest to date for this problem—showed that women with breast cancer continued to report cognitive deficits for as long as six months after finishing treatment. That study not only validated that chemo-brain was pervasive, but Janelsins and...
Breast Cancer Research and Treatment . 2012 (1)Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from...